Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2019

Suzy M Teutsch, Carlos A Nunez, Anne Morris, Skye McGregor, Jonathan King, Julia ML Brotherton, Daniel Novakovic, Robert Booy, Cheryl A Jones, William Rawlinson, Bruce R Thorley and Elizabeth J Elliott

# Abstract

The Australian Paediatric Surveillance Unit (APSU) has been prospectively collecting national data on rare childhood conditions since 1993, with monthly reporting of cases by paediatricians. In this report we describe annual results from studies for ten communicable diseases and complications of communicable diseases that were conducted using APSU surveillance in 2019 and place these in an historic context. Results are reported on acute flaccid paralysis, congenital cytomegalovirus infection, neonatal herpes simplex virus infection, perinatal exposure to HIV, paediatric HIV infection, severe complications of seasonal influenza, juvenile onset recurrent respiratory papillomatosis (JoRRP), congenital rubella syndrome, congenital varicella syndrome and neonatal varicella infection. APSU provides rich clinical data to complement data collected from other surveillance systems and to improve understanding and response to rare childhood infections.

Keywords: Australia, child, public health surveillance, rare diseases, communicable diseases

# Introduction

For over 26 years the Australian Paediatric Surveillance Unit (APSU) has conducted national monthly surveillance of rare medical conditions in childhood, including communicable and non-communicable diseases. APSU facilitates surveillance and collection of prospective national data on several conditions simultaneously using an active mechanism, with reporting by paediatricians. Each month paediatricians are prompted to notify newly diagnosed cases of conditions currently under surveillance; those who notify cases are then asked to provide detailed demographic, clinical and outcome data. These unique data have filled knowledge gaps, enabled estimation of disease incidence and analysis of disease trends over time, and contributed to research, clinical practice and policy development.1 In 2019, APSU conducted surveillance for eight communicable diseases and complications of communicable diseases; the results are detailed in this report.

## Characteristics of the APSU surveillance system

The APSU surveillance mechanism is well-established, robust and flexible (Text box 1). APSU is able to respond rapidly to changing public health priorities, such as inclusion in 2008 of a study on severe complications of seasonal influenza surveillance following a surge in childhood admissions and deaths.2,3 We maintain currency of the database of contributors through our relationship with the Royal Australasian College of Physicians. Individual clinicians and researchers and research groups may apply for inclusion of a study for APSU surveillance. We convene a national investigator group to develop the study protocol, review and classify cases, analyse and report results. APSU data are collected from metropolitan, rural and regional clinicians, include children seen as both in- and out-patients, are clinically rich, and complement data collected by existing surveillance systems. Electronic reporting and the low frequency of rare conditions requires minimal workload for paediatricians, as reflected in their high and sustained participation rate: over 90% (333,003/352,944) of all monthly report cards sent in the first 25 years were returned. APSU has been evaluated using CDC criteria for surveillance systems4 and met criteria for usefulness, simplicity, acceptability and representativeness, sensitivity and timeliness of data quality. Clinicians support the APSU, reporting that it is valuable for generating knowledge (81%), identifying research priorities (78%), guiding clinical practice (70%) and informing public health policy (70%). Similar responses were received from researchers and public health professionals.4

****Text box 1. Characteristics of the APSU surveillance system****

* Surveillance and research resource available to researchers, research groups nationally
* Targets rare childhood disorders, including communicable and vaccine-preventable disease
* Flexible and responsive to public health needs
* Dedicated, updated, relevant and representative database of paediatricians
* Prospective, national surveillance using monthly ‘active’ reporting mechanism
* Includes inpatients and outpatients in urban/regional/rural/remote/very remote regions
* Internationally recognised diagnostic criteria and study protocol provided to contributors
* Simple reporting process, acceptable to contributing paediatricians, with minimal workload
* Electronic report card used by 95% of clinicians: high response rate to monthly card (> 90%)
* Data capture using secure REDCap system: high completion rate of case report form
* Data are timely, sensitive: enhance and complement other surveillance systems
* Member of the International Network of Paediatric Surveillance Units

## Surveillance method

The APSU surveillance method has been described in detail elsewhere.5 Between 1 January and 31 December 2019, a report card listing 14 rare medical conditions in children was distributed each month, either by email (95%) or as a reply-paid paper card (5%), to 1429 paediatricians located across Australia. These clinicians were registered with the APSU as ‘contributors’ and were considered to be ‘active’ (i.e. they worked as clinicians, had agreed to report to the APSU and were not on leave). The 14 conditions listed on the 2019 report card (Figure 1) could be categorised as either rare communicable diseases or complications of rare communicable diseases, rare genetic disorders or uncommon injuries and other conditions.

Figure 1. Example APSU monthly report card in 2019

Figure 1 depicts an image of an example APSU electronic report card that was sent out to all paediatricians who actively reported cases to the APSU (i.e. APSU contributors) in August 2019. At the top of the card, it asks APSU Contributors if they have ““nothing to report” to reply to the card with “NTR” in the subject line. Moving down the card, study updates are listed, followed by 15 conditions under surveillance, including the ten communicable diseases and complications of communicable diseases described in this annual report. APSU Contributors are asked to indicate on the card whether they have recently seen a child having one or more of the conditions listed. If APSU Contributors have seen a child with one or more of the conditions listed, they are asked on the card to return it with the number of children they have seen with the condition and to complete a case report form (CRF) for each child, either by accessing the APSU website or by clicking on the hyperlink listed next to each condition (will enable the CRF to be completed online) and to return the card and completed CRF to the APSU. If APSU Contributors report a case, they are asked to record patient’s details for later reference.


The ten rare communicable diseases and complications of rare communicable diseases under APSU surveillance in 2019 and listed on the report card were: acute flaccid paralysis, congenital cytomegalovirus infection, neonatal herpes simplex virus infection, perinatal exposure to HIV, paediatric HIV infection, severe complications of seasonal influenza, juvenile onset recurrent respiratory papillomatosis (JoRRP), congenital rubella syndrome, congenital varicella syndrome and neonatal varicella infection.

Upon receipt of the monthly APSU report card (Figure 1), paediatricians were asked to notify whether or not they had seen a child with one or more of the conditions listed on the card during the previous month and to return the card to the APSU. Paediatricians who notified a case were sent the link to a case report form (also available on the electronic card) requesting de-identified demographic, clinical, laboratory, treatment and outcome data on the child. Data from case report forms are collected using the secure REDCap system and automatically downloaded into a database for checking and safe storage. Case report forms were forwarded to study investigators with expertise in each of the specific conditions so that cases could be confirmed.

## Results

### Representativeness of mailing list

In 2019 the number of children aged 0–14 years who were living in Australia was 4.7 million or 19% of the total population.6 Of the children, 51% were boys, 5.9% were Aboriginal or Torres Strait Islander; 70% lived in major cities and 2% lived in remote/very remote regions; 21% live in the lowest and 20% in the highest socioeconomic areas; and 82% lived in couple families.6 The distribution of the child population by state is shown in Table 1.7

Table 1. Number and proportion of APSU Contributors (n = 1,429) and of children aged 0–14 years by Australian state and territory

| APSU contributors n = 1,429 | n (%) contributors | Children 0–14 years | % children 0–14 years |
| --- | --- | --- | --- |
| **Australia** |  |  |  |
| Paediatricians | 1,334 (93.4%) | 4,741,629 | 100 |
| Other specialtiesa | 95 (6.6%) |  |  |
| **New South Wales (NSW)** |  |  |  |
| Paediatricians | 498(34.8%) | 1,499,863 | 31.7 |
| Other specialties | 41 (2.9%) |  |  |
| **Victoria (Vic)** |  |  |  |
| Paediatricians | 322 (22.6%) | 1,201,923 | 25.3 |
| Other specialties | 20 (1.4%) |  |  |
| **Queensland (Qld)** |  |  |  |
| Paediatricians | 227 (15.9%) | 989,916 | 20.9 |
| Other specialties | 12 (0.8%) |  |  |
| **Western Australia (WA)** |  |  |  |
| Paediatricians | 139 (9.7%) | 511,842 | 10.8 |
| Other specialties | 9 (0.6%) |  |  |
| **South Australia (SA)** |  |  |  |
| Paediatricians | 85 (6.0%) | 308,953 | 6.5 |
| Other specialties | 4 (0.3%) |  |  |
| **Tasmania (Tas)** |  |  |  |
| Paediatricians | 26 (1.8%) | 94,123 | 2.0 |
| Other specialties | 3 (0.2%) |  |  |
| **Australian Capital Territory (ACT)** |  |  |  |
| Paediatricians | 20 (1.4%) | 81,390 | 1.7 |
| Other specialties | 6 (0.4%) |  |  |
| **Northern Territory (NT)** |  |  |  |
| Paediatricians | 17 (1.2%) | 52,840 | 1.1 |
| Other specialties | 0 (0%) |  |  |

a Other specialties include surgery, psychiatry, anaesthetics, general practice, nuclear medicine, obstetrics, sexual health medicine.

In 2019, the 1,429 paediatricians reporting to the APSU (‘APSU Contributors’) worked in every Australian state and territory. This number represents approximately 90% of paediatricians in clinical practice in Australia and all hold a Fellowship of the Royal Australasian College of Physicians or equivalent. The proportion of paediatricians and other specialists by state/territory was similar to the proportion of resident children (Table 1). Contributors were based in major cities, inner and outer regional and remote areas. They included general and sub-specialist paediatricians (Table 2) and some other specialists (e.g. paediatric surgeons and psychiatrists) working in child health in both inpatient and outpatient settings.

Table 2. Distribution of paediatriciansa contributing to APSU by specialty (n = 1,334)

| Specialty | 1,334 (%) |
| --- | --- |
| Paediatric subspecialty (other) | 451 (33.8%) |
| General paediatrics | 424 (31.8%) |
| Neonatology | 186 (13.9%) |
| Community child health/Developmental | 183 (13.7%) |
| Emergency | 69 (5.2%) |
| Intensive Care | 17 (1.3%) |
| Clinical pharmacology | 2 (0.1%) |
| Clinical epidemiology | 1 (0.1%) |
| Forensics | 1 (0.1%) |

a The other 95 APSU contributors belong to other specialties e.g. surgery, psychiatry.

The overall return rate by paediatricians of the monthly APSU report card was 91.8% in 2019. This includes case notifications and ‘nothing to report’ responses. In comparison, the response rate has been over 90% for 26 years and in 2018 was 92.0%.5

## Conditions under surveillance

Table 3 lists the communicable diseases currently under surveillance and shows the duration of the study, and the total number of cases identified, the number of cases confirmed in 2019 and an estimate of minimum incidence for both 2019 and the entire study period.

Table 3. Confirmed cases identified by the APSU during the period 1 January – 31 December 2019 and for the total study period, and estimated incidence per 105 children of the relevant population/age per annum, by condition

| Communicable disease or complication of communicable disease | Surveillance study date of commencement | Confirmed cases for Jan–Dec 2019 | Incidence estimate per 105 per annum and 95% CI for 2019 | Confirmed cases for the whole study period to Dec 2019 | Incidence estimate per 105 per annum for the whole study period to Dec 2019 |
| --- | --- | --- | --- | --- | --- |
| Acute flaccid paralysis (AFP) | March 1995 | 63a | 1.34 [1.02–1.70]b | 1,132 | 1.04 [0.98–1.10]b |
| Congenital cytomegalovirus | Jan 1999 | 15 | 5.28 [2.77–8.17]c | 362 | 5.97 [5.37–6.62]c |
| Congenital rubella infection | May 1993 | 0 | 0 | 54 | 0.71 [0.53–0.93]c |
| Congenital varicella syndrome | May 2006 | 0 | 0 | 3 | 0.07 [0.01–0.21]c |
| Congenital varicella syndrome | 1995–1997d |  |  | 6 | 0.80 [0.30–1.80]c |
| Neonatal varicella infection | May 2006 | 3 | 0.99 [0.20–2.90]c | 31 | [0.49–1.03]c |
| Neonatal varicella infection | 1995–1997d |  |  | 44 | 5.80 [4.30–7.80]c |
| Juvenile-onset recurrent respiratory papillomatosise | Sep 2011 | 0 | 0 | 17 | 0.04 [0.02–0.07]b |
| Neonatal herpes simplex virus (HSV) infection (< 3 months) | Jan 1997 | 8 | 2.64 [1.14–5.21]c | 208 | 3.19 [2.78–3.66]c |
| Perinatal exposure to HIV | May 1993 | 59 | 19.49 [14.84–25.14]c | 852 | 11.28 [10.53–12.06]c |
| Paediatric HIV infection | May 1993 | 0 | 0 | 87 | 0.07 [0.06–0.09]f |
| Severe complications of influenzag | 2008 (flu season only) | 62 | 1.32 [1.00–1.68]b | 695 | 1.31 [1.22–1.41]b |

a Includes all cases of acute flaccid paralysis (AFP) reported via the APSU/NERL and PAEDS. All cases have been classified by the Polio Expert Panel (PEP) as ‘non-polio AFP’ according to WHO criteria.

b Based on population of children aged < 15 years.

c Based on number of live births.

d See reference 38.

e Includes both confirmed cases (visualisation on endoscopy, histological confirmation) and probable cases (visualisation on endoscopy, no histology report).

f Based on population of children aged < 16 years.

g Influenza surveillance was conducted each year during the influenza season, from July to September for 2008 and 2010–2015; June to October in the 2009 pandemic year; and June to September 2016–2019

## Acute flaccid paralysis (AFP)

Since 1995, the APSU has conducted AFP surveillance at the request of the Australian Government. AFP is the clinical presentation for, and thus a marker of, acute poliomyelitis; surveillance and investigation of AFP cases is critical to ensure that Australia retains its polio-free certification by the World Health Organization (WHO).

Suspected cases of AFP in children aged less than 15 years were reported to the National Enterovirus Laboratory (NERL) at the Victorian Infectious Diseases Reference Laboratory via one of two separate but complementary mechanisms: by individual clinicians, who notified a case to APSU or NERL and completed the APSU case report form, or via the Paediatric Active Enhanced Disease Surveillance system (PAEDS). PAEDS employs research nurses at seven designated paediatric hospitals to identify new cases of AFP in inpatients and to complete a case report form based on the APSU form. Stool samples were collected via both surveillance mechanisms. WHO defines an adequate stool sample as being two stools of sufficient quantity for laboratory analysis and collected at least 24 hours apart, within 14 days after the onset of paralysis. All reported AFP cases were confirmed and classified by the Polio Expert Panel (PEP) at bi-monthly teleconference meetings for reporting to the WHO. APSU has membership of the PEP.

In 2019, there were 83 AFP notifications via the APSU/NERL and PAEDS surveillance mechanisms for all of which case report forms were provided. There were 14 duplicates and six errors (did not fulfil the case definition, including three cases outside the age range) and 63 confirmed AFP cases. Seven cases were reported by paediatricians who work outside hospitals surveyed by PAEDS and would otherwise have been missed.

Of the 63 confirmed AFP cases, all were classified as non-polio AFP by the PEP. Thus, Australia’s non-polio AFP rate in 2019 was 1.34 per 105 children under 15 years of age. This meets the WHO reporting target for sensitive AFP surveillance of 1 per 105 children aged < 15 years per annum.8 Adequate stool samples were collected from 31 cases (49%).

All 63 children with AFP were Australian-born and eight (12.7%) were Indigenous. Ethnicity was not recorded for two children. Of the confirmed cases, 23 were reported in New South Wales, 18 in Victoria, 11 in Queensland, four in Western Australia, two each in South Australia, Tasmania, and the Northern Territory and one in the Australian Capital Territory.

The most common diagnoses in AFP cases were: Guillain-Barré syndrome (GBS) in 18 cases (29%), transverse myelitis in 11 cases (18%), acute disseminated encephalomyelitis (ADEM) in five cases (8%) and spinal cord compression in two cases (3%), which is consistent with previous years.5 One case of acute flaccid myelitis was recorded.

Since AFP surveillance commenced 24 years ago, 1,132 cases have been confirmed. The case rate has continuously remained above 1 per 105 children aged less than 15 years each year since 2008,9 contributing to Australia’s status as polio-free.8 We have recently reported the newly described entity acute flaccid myelitis using the AFP database.10

In 2019, a report of Australian AFP cases was published each fortnight in the WHO Regional Office for the Western Pacific Polio Bulletins; these cases contributed to the 2019 National Certification and Regional Certification Committee reports11 that enable Australia to be declared polio-free. AFP data were also published in the PAEDS annual report to Communicable Diseases Intelligence in 2019.12 Ongoing surveillance of AFP in Australia remains important as poliomyelitis persists in several countries and Australia remains at risk of imported infection.8

## Congenital cytomegalovirus infection (cCMV)

Congenital CMV infection is transmitted from infected mothers to their unborn children during pregnancy. It is often asymptomatic but can result in severe sequelae, notably hearing loss and developmental delay,13 justifying screening for CMV in children with sensorineural hearing loss.14 There is no vaccine available to prevent CMV infection; however, antiviral treatment including ganciclovir and valganciclovir is recommended for symptomatic cCMV and is thought to be effective in improving developmental and hearing outcomes. 15 APSU surveillance of cCMV infection commenced in 1999.

In 2019, there were 16 notifications. One case report was not returned. Twelve neonates in the first three weeks of life had confirmed cCMV infection (mostly diagnosed by PCR on urine or Guthrie blood spot) and three who presented later with symptoms had suspected cCMV. Based on 15 cases, the incidence estimate was 5.28 per 105 births in 2019. Ethnicity was reported for 14 infants: two were Indigenous. Six infants were reported from Queensland, five from NSW, and two each from Victoria and the Northern Territory. No infant with cCMV was reported from South Australia, Western Australia, Tasmania or the Australian Capital Territory.

Clinical characteristics of the 15 infants included: deafness (6), small for gestational age (6), jaundice (5), petechiae or purpura (4), thrombocytopenia (3), microcephaly (3) and anaemia (2). Hepatitis and developmental delay were each reported in one infant. Six of the 15 infants were treated with valganciclovir and all were alive at the time of reporting.

A symptomatic illness suggestive of CMV infection was reported during pregnancy in four of the 15 mothers (27%) and positive CMV serology was reported in 11/15 (73%). Serology was unknown or not tested in four mothers.

In 21 years of APSU surveillance for cCMV, a total of 362 confirmed cases was reported: 195 during the first 11 years, 1999–2009,14 and 167 during the next 10 years. APSU data collected from 1999 to 2016 showed no increase over time in the number of infants with symptomatic CMV infection but did show an increase in the number of symptomatic infants who received antiviral treatment.15 Over 40% of their mothers reported a symptomatic illness suggestive of CMV infection during pregnancy and this correlated with positive CMV serology in these mothers. Hearing loss and developmental delay were prevalent in both symptomatic and asymptomatic infants. Bartlett recommended the introduction of universal newborn screening for cCMV infection in infants.15

Most cases reported to the APSU are asymptomatic (71%) and thus surveillance is likely to underestimate the true incidence of cCMV infection. APSU data do show that children with asymptomatic cCMV are at increased risk of hearing loss but have similar neurodevelopmental outcomes to healthy controls.16 APSU data have contributed to a range of educational resources for health professionals, carers and the community regarding prevention and management of cCMV disease,5 and have influenced clinical care and thinking about screening.14,15

## Neonatal herpes simplex virus infection (HSV)

HSV infection in neonates and young infants is transmitted either during birth or soon after delivery, most commonly from mothers with primary genital HSV infection.17,18 Neonatal HSV infection manifests either as disease localised to specific organs (e.g. the skin, eyes or mouth or the central nervous system) which ranges from mild to severe, or as disseminated disease which is more likely to result in severe outcomes including death or disability.18,19 There is no vaccine available to prevent neonatal HSV infection; however, antiviral treatment with acyclovir has been available and recommended for infants since the 1980s.20 The APSU has conducted surveillance for this condition since 1997.

In 2019, there were nine notifications to the APSU of neonatal HSV infection in infants aged less than three months. Eight were confirmed as cases and for one child no case report form was received. The estimated incidence rate of neonatal HSV infection was 2.64 per 105 births in 2019.

Of the eight confirmed cases, four had HSV-1 and four had HSV-2 infection. Two infants had disseminated disease with neurological involvement (one with HSV-1, who died, and one with HSV-2). Six of the infants had disease localised to the central nervous system, two of whom also had skin lesions, and both survived. All infants received antiviral treatment with acyclovir at diagnosis. The infant who died received acyclovir and antibiotics (benzylpenicillin and gentamicin) until the time of death.

Two cases were reported from New South Wales, two from Victoria, three from Western Australia and one from Queensland. No cases were reported in South Australia, Tasmania, the Northern Territory or the Australian Capital Territory. Ethnicity was recorded for five cases and none was Indigenous.

In the 23 years since APSU surveillance for neonatal HSV commenced, a total of 208 confirmed cases has been reported, the annual frequency fluctuating over time. Case numbers were highest in 2015 (16 cases) and lowest in 2017 (two cases).

In 2019, we conducted an analysis of 193 cases of neonatal HSV infection reported to the APSU over a 22-year period (1997–2018). Of these, 83 had neurological disease, either localised to the central nervous system or disseminated and caused by HSV-1 (55%) or HSV-2 (45%). Children with neurological disease were more likely to have disseminated disease, increased mortality, and abnormal neuroimaging compared with infants with HSV infection without neurological involvement (unpublished data).

## Perinatal exposure to HIV and paediatric HIV infection

APSU surveillance for perinatal exposure to HIV in children born to women infected with HIV, and HIV infection in children aged less than 16 years, has been conducted since 1993 in collaboration with the Kirby Institute, previously the National Centre for HIV Epidemiology and Clinical Research.21 Mother-to-child transmission (MTCT) of HIV, although now uncommon (~2%), is the most frequent cause of HIV infection in Australian children.21 Prevention of perinatally-acquired HIV infection by MTCT includes maternal antiretroviral treatment during pregnancy; prophylactic antiretroviral treatment of the infant; caesarean section delivery; and avoiding breastfeeding.

In 2019, there were 63 notifications of perinatal exposure to HIV to the APSU. Four were duplicate reports; 59 cases of perinatal exposure to HIV were confirmed. In two of these cases MTCT was confirmed; a rate of 3.38%. One child was born to a woman with undiagnosed HIV at birth (vaginal delivery, breast fed, no antiretroviral treatment). The mother of the second child was known to have HIV but did not receive antiretroviral treatment. HIV test results were not reported for 15 of the infants by the end of 2019. In 2019, the estimated incidence of perinatal exposure to HIV was 19.49 per 105 births. The number of reported cases varies by year and in 2019 was double that reported in 2018 for perinatal exposure (29 cases) and perinatal transmission (one case).

All infants were born in Australia and three were Indigenous. Eighteen cases were confirmed in each of New South Wales and Western Australia, five in Victoria, four in the Australian Capital Territory and three in Queensland. No case was reported in South Australia, Tasmania or the Northern Territory. For 11 cases no geographic location was recorded.

Information on management was available for 34 mothers, 31 of whom received antiretroviral treatment during pregnancy. Mode of delivery was vaginal in 17, by emergency caesarean section in 9 and elective caesarean section in 5 infants. Three reports did not include the mode of delivery. Of the mothers, 23 were known to have been born overseas and 2 identified as Aboriginal.

Since surveillance commenced 26 years ago, a total of 852 confirmed cases of perinatal exposure to HIV and 87 confirmed cases of paediatric HIV infection have been reported to the APSU. During this time, we documented a fall in MTCT from 39% in the 5-year period 1985–1991 to 28% in 1992–1996 and 2% in 2012–2016.21

There were no reported cases of paediatric HIV infection in 2019, the last cases (three children born overseas) having been reported to the APSU in 2014.22

Data on perinatal HIV exposure and perinatal HIV transmission in Australian-born infants and paediatric HIV infections are routinely reported in the Australian Annual Surveillance Report on HIV, viral hepatitis and sexually transmissible infections,23 and contribute to the National HIV Strategy.24 Data are also routinely reported to the Joint United Nations Programme on HIV/AIDS (UNAIDS)25 as part of international reporting on mother-to-child transmission of HIV.

## Severe complications of influenza

APSU surveillance of severe complications of laboratory-confirmed influenza virus infection in hospitalised children aged under 15 years has been conducted during the Australian winter season (1 June to 30 September) since 2008. Children are vulnerable to developing severe complications, leading to high rates of hospitalisation, morbidity and mortality.26

In 2019, 77 notifications were reported to the APSU, with case report forms completed for 76. There were 62 confirmed cases; the remainder were classified as duplicates (3) or errors (11). In contrast there were only 20 confirmed cases reported in 2018, which correlates with other reports of the severity of the 2019 influenza season.27 The estimated incidence rate was 1.32 per 105 children aged under 15 years.

Thirty-nine confirmed cases had influenza A infection (two with influenza A H1N1) and 23 cases had influenza B infection. Fifty-two children (84%) had no underlying medical condition.

The severe complications reported involved multiple organ systems, including the respiratory, central nervous, renal, musculoskeletal, cardiac, gastrointestinal and haematological systems. Pneumonia was the most common complication, recorded in 24 children (39%), followed by seizures in eight (13%), rhabdomyolysis in eight (13%), and bacterial co-infection in seven children (11%). Twenty children (32%) were admitted to an intensive care unit and seven (11%) required mechanical ventilation. Thirty-three (53%) required oxygen therapy. Of the children, 28 (45%) received antiviral treatment (oseltamivir), and one received both oseltamivir and acyclovir. Forty-three children (69%) received antibiotics. Only five children were recorded as having received the seasonal influenza vaccine. The vaccination status was unknown for 41 children.

At the time of reporting to the APSU, two children had died and five remained in hospital. The two children who died were under five years of age and both had encephalitis/encephalopathy, one with seizures and the other with pneumonia. Both children were treated with oseltamivir and antibiotics. One child had influenza A and one child had influenza B. Neither child had an underlying medical condition or had been vaccinated against seasonal influenza.

Twenty-six cases were reported in New South Wales, 19 in Queensland, six in Victoria, six in Western Australia, three in the Australian Capital Territory and two in Tasmania. No cases were reported in South Australia or the Northern Territory. Ethnicity was recorded for 57 cases; two cases were Indigenous.

In the twelve seasons since APSU surveillance for severe complications of influenza commenced, a total of 695 confirmed cases have been reported. The annual number of cases has fluctuated: the highest number was reported during the 2009 H1N1 pandemic and in 2017 (106 cases in each year), and in 2015 (82 cases), while the lowest number of cases was reported in 2018 (20 cases). Data from ten years of APSU surveillance 2008–2017 will be submitted for publication in 2020. It showed that over half the children with severe complications were previously healthy, almost half required ICU, the most common complication was pneumonia, vaccination rates were very low, and antivirals were underutilised (unpublished).

## Juvenile-onset recurrent respiratory papillomatosis (JoRRP)

JoRRP is a rare disease resulting from perinatal exposure of the airways to human papillomavirus (HPV) in the maternal genital tract. In children who develop the disease, which is typically due to infection with Human Papillomavirus (HPV) types 6 or 11, the infection is not cleared by the immune system and persists in the child’s respiratory tract, giving rise to the development and recurrence of benign papillomata, typically affecting the larynx and causing airway obstruction.28–30

In 2007, Australia established a national HPV vaccination program for females aged 12–26 years of age, which includes protection against HPV types 6 and 11. Since the program commenced, rates of HPV6 and 11 infection and associated genital warts have fallen dramatically).31,32 Since October 2011, surveillance of JoRRP has been conducted by the APSU and, using this surveillance approach, Australia was the first country to demonstrate that JoRRP is preventable by vaccination of females of child-bearing age.30 To ensure capture of JORRP cases, specialist paediatric otolaryngologists who treat the disease were enrolled as contributors to monthly APSU surveillance. The aim of JORRP surveillance is to monitor the incidence of the disease, describe the epidemiology of cases including maternal history, monitor the viral types associated with disease and describe treatment modalities in use.

In 2019, no cases of JoRRP were reported to the APSU in any Australian state or territory for the second consecutive year. Of two cases reported in 2017, one was a probable case of non-laryngeal JoRRP and the other occurred in a child who was not born in Australia. This suggests that widespread vaccination of females and, since 2013, routine vaccination of males, has interrupted community circulation of the causal HPV types for JoRRP and correspondingly dramatically reduced the risk of perinatal exposure and subsequent disease in Australia. In the eight years of JoRRP surveillance, 17 confirmed cases were reported, with one to four cases identified per year until the end of 2017.

Novel data from the APSU JoRRP study have been published30 and were presented in 2019 by Chief Investigator Associate Professor Daniel Novakovic at the World Phonosurgery Congress in Buenos Aires Argentina and at the ASEAN ORL-HNS Congress in Singapore.

## Congenital rubella syndrome

Congenital rubella syndrome is a vaccine-preventable condition caused by maternal rubella infection during pregnancy, which can result in fetal death or congenital defects including heart disease, deafness and blindness, neurological abnormalities and developmental delay.33

APSU surveillance of congenital rubella commenced in 1993. Paediatricians are asked to notify any cases in children or adolescents aged up to 16 years with definite or suspected congenital rubella infection with defects, based on history, clinical and laboratory findings.

In 2019, there were no cases of congenital rubella reported to the APSU in any Australian state or territory. This was consistent with the lack of notifications to the National Notifiable Disease Surveillance System in 2019. This is a passive surveillance system with reporting from laboratories and state/territory health departments. Together the two methods provide excellent case ascertainment.34 No notifications of congenital rubella have been reported to the APSU since 2015, when two cases were reported, one with confirmed congenital rubella syndrome.35

Since surveillance commenced, a total of 54 confirmed cases of congenital rubella infection have been reported to the APSU in 26 years, and 35 of these cases have been confirmed as having congenital rubella syndrome. Twenty-nine cases were reported during the first eleven years of surveillance (1993–2013) and five during the subsequent ten years (2004–2013),32 most likely due to increased uptake of rubella vaccination in young women and infants.

Rubella immunisation for adolescent women was introduced in Australia in 1971. Immunisation of infants at 12 months with the measles-mumps-rubella (MMR) vaccine was introduced in 1989.33 The majority of children identified with CRS during the study period have been born to women from countries without national vaccination programs,33 thus ongoing vigilance is required. Conscientious objection to vaccination persists in specific regions of Australia and contributes to a lower than average uptake of the measles-mumps-rubella-varicella vaccine, putting unborn children at potential risk.36

## Neonatal varicella virus infection and congenital varicella syndrome

Varicella zoster virus infection in young infants can be acquired either congenitally or in the neonatal period. Congenital varicella syndrome can result in eye, neurological, cardiovascular, or gastroenterological abnormalities, developmental delay, blindness and typical cicatricial skin lesions.37

Neonatal varicella infection occurs in the first month of life with rash and fever developing after either exposure to an infected person or through maternal infection in the last 4 weeks of pregnancy. APSU surveillance for congenital and neonatal varicella infection commenced in 2006, following the introduction of universal vaccination for infants in 2005.38

In 2019, three cases of neonatal varicella infection were notified to the APSU. All presented with skin lesions consistent with varicella infection, all were hospitalised, two were treated with acyclovir and all were discharged well. Maternal infection was reported for one case. All of the infants were born in Australia: the mothers of two of the infants were born overseas and the country of birth was unknown for the mother of the third infant. In 2019, the estimated incidence rate was 0.99 per 105 births.

A total of 31 cases of neonatal varicella infection have been reported to the APSU in the 14 years since the current surveillance commenced in 2006. This contrasts with APSU data collected in a previous study over three years (1995–1997), prior to the introduction of varicella vaccination, when 44 cases of neonatal varicella were reported.

There were no notifications of congenital varicella syndrome reported to the APSU in 2019. A total of three confirmed cases have been reported to the APSU since surveillance commenced in 2006. The last confirmed case of congenital varicella was notified in 2017. This contrasts with APSU data collected in a previous study during 1995–1997, prior to the introduction of routine varicella vaccination, when six cases were reported.38

Although the current Immunisation Schedule provides free vaccination to children, catch-up for adolescents to age 20 years and to refugee and humanitarian entrants to Australia,39 ongoing surveillance of varicella is important to identify infants born to unvaccinated women born in Australia or overseas.

# Discussion and conclusions

The APSU provides a unique active surveillance mechanism that allows collection of detailed and timely clinical data on rare childhood disorders from a representative group of contributors (paediatricians and other child health specialists nationally). The surveillance mechanism is well-established and robust and complements other national data collections.

The participation rates by contributors is high and sustained. In 2019, 1426 contributors reported to the APSU with a monthly return rate of the surveillance card of 91.8%. A reporting rate of at least 90% was achieved over the last 25 years. General and sub-specialist paediatricians report cases from urban centres, regional and remote areas.

In 2019, 14 rare conditions, including eight communicable diseases or complications of communicable diseases (acute flaccid paralysis, congenital cytomegalovirus infection, neonatal herpes simplex virus infection, perinatal exposure to HIV and paediatric HIV infection, severe complications of seasonal influenza, juvenile onset recurrent respiratory papillomatosis (JoRRP), congenital rubella syndrome, congenital varicella syndrome and neonatal varicella infection), were under surveillance. APSU confirmed cases of all conditions apart from JoRRP, congenital rubella syndrome and congenital varicella syndrome.

WHO’s target for AFP incidence of at least 1 case per 105 children aged under 15 years of age per annum was achieved in 2019, as has been the case for many years. Regular review and classification of AFP cases collected by APSU, NERL and PAEDS is undertaken by the Polio Expert Panel Committee. All 2019 cases were classified as non-polio AFP and reported to the WHO, contributing to Australia’s status as polio-free. GBS, transverse myelitis and ADEM accounted for most cases of AFP and one case of the novel condition acute flaccid myelitis was identified. While there is a threat of importation of poliomyelitis, ongoing surveillance is required.

The number of children with severe complications of influenza was high in 2019, reflecting the high community prevalence of seasonal influenza. Few children in this group had documented seasonal vaccination, however influenza vaccination uptake in children aged six months to five years has increased nationally from <5% in 2017 to 39.7% in 2019 [Beard et al 2020]. This follows changes to the National Immunisation Program in 2018, which saw recommendations and funding for seasonal influenza vaccination in six Australian states and territories for all children aged under five years, and additionally to all Aboriginal and Torres Strait Islander children aged five to 14 years.40 The fact that 60% of children admitted with severe influenza complications were previously healthy supports universal vaccination and identifies the need for ongoing education for the community and healthcare workers about the need to vaccinate children. Outcomes are worse for children with influenza and co-infection, and the convergence of the upcoming influenza season with the COVID-19 pandemic is of concern. The APSU can respond rapidly to this emerging disease threat and will monitor co-infection with COVID-19 and influenza and its outcomes in children reported with influenza complications in 2020.

The frequencies of cCMV and neonatal HSV infection in infants have remained at similar levels since the late 1990s. These conditions are transmitted from mothers to infants and are not vaccine-preventable, however our results indicate a need for increased awareness by health professionals and the community, and for maternal screening for these infections in order to prevent potentially devastating outcomes including death and disability. The cCMV and neonatal HSV infection studies are the longest continuously-running surveillance studies of these diseases internationally and allow for a thorough analysis of trends over time in response to changes in policy, diagnostics, treatment and vaccination strategies.

Our longstanding collaboration with the Kirby Institute provides data collected since 1993 on over 852 confirmed cases of perinatal exposure to HIV infection. Trends over time include a significant fall in the number of women in whom HIV infection was not diagnosed before or during pregnancy and an accompanying increase in the number of LSCS deliveries, use of antiretrovirals in mother and infant, and exclusively bottle-fed babies. These interventions in turn have decreased in the number of cases of mother-to-child transmission to < 5%. Nevertheless, many perinatally exposed children are born in Australia to mothers who were born overseas, including 23/30 cases reported to the APSU in 2019 for whom the mother’s birthplace was known. These data highlight that there remain high risk groups in whom screening for HIV during pregnancy should be universal.

There has been an ongoing decline in the numbers of cases of congenital rubella syndrome, neonatal varicella infection, congenital varicella and JoRRP reported to APSU since surveillance commenced for these conditions This decline in case numbers for these conditions persisted in 2019 and reflects increased vaccine availability and uptake over time. Continued surveillance is required as children of immigrant and refugee women from countries without vaccination programs remain vulnerable to these conditions. Although overall coverage of the measles-mumps-rubella-varicella (MMRV) vaccine was high in infants aged 24 months in Australia in 2017 (92%), lower coverage (< 85%) was observed in specific regions, leaving some groups vulnerable.36

We thank all Australian paediatricians for their ongoing, voluntary contribution to APSU surveillance and for providing data to inform clinical care, policy and prevention. We also acknowledge the contribution and expertise of all researchers, clinicians and research groups who use the APSU mechanism.

# Acknowledgements

We thank the APSU Scientific Review Panel (Carol Bower, David Burgner, Fiona Mackie, Mavis Duncanson and David Lester-Smith) for providing expertise that has greatly assisted in study development.

APSU acknowledges the contribution of study coordinators Linda Hobday and Arnau Garcia Clapes (AFP), Ece Egilmezer and Susanne Booth (cCMV), Dr Gulam Khandaker (Congenital Rubella Infection, Congenital Varicella Syndrome and Neonatal Varicella Infection) and Jocelynne McRae (PAEDS Coordinator – Research Nurse).

We would also like to acknowledge the continued contribution of all Australian paediatricians and other child health professionals who participate in surveillance studies conducted by the APSU. Special thanks goes to APSU Administration Officer Dannielle Handel for the management of the APSU database.

APSU activities are supported by the Australian Government Department of Health; The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health; The Children’s Hospital at Westmead; and the Royal Australasian College of Physicians. Elizabeth Elliott is supported by an NHMRC MRFF Practitioner Fellowship (#1135959).

# Authors’ details

**Dr Suzy M Teutsch**

Research Fellow, The Australian Paediatric Surveillance Unit; The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health; and The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales.

**Dr Carlos A Nunez**

Research Associate, The Australian Paediatric Surveillance Unit and The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health and The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales.

**Dr Anne Morris**

Senior Research Fellow, The Australian Paediatric Surveillance Unit; and Paediatrician and Senior Lecturer, The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health and The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales.

**Professor Robert Booy**

Senior Professorial Fellow, National Centre for Immunisation Research and Surveillance, Sydney, New South Wales.

**Dr Skye McGregor**

Epidemiologist, The Kirby Institute, UNSW Australia, Sydney, New South Wales.

**Mr Jonathan King**

Epidemiologist, The Kirby Institute, UNSW Australia, Sydney, New South Wales.

**Associate Professor Julia ML Brotherton**

Medical Director, VCS Population Health, VCS Foundation; and Honorary Principal Fellow, Melbourne School of Population and Global Health, University of Melbourne, Victoria.

**Associate Professor Daniel Novakovic**

ENT, Head and Neck Surgeon, Laryngologist, and Director, Dr Liang Voice Program, The University of Sydney, Faculty of Medicine and Health, Central Clinical School, Sydney, New South Wales.

**Professor Cheryl A Jones**

Dean and Head of Sydney Medical School, The University of Sydney, Faculty of Medicine and Health, Sydney, New South Wales.

**Professor William Rawlinson**

Senior Medical Virologist, Director of Serology, Virology and OTDS Laboratories, NSW Health Pathology Randwick, Sydney, New South Wales.

**Associate Bruce R Thorley**

Head, National Enterovirus Reference Laboratory and WHO Polio Regional Reference Laboratory, Victorian Infectious Disease Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria.

**Professor Elizabeth J Elliott**

Professor of Paediatrics and Child Health and Director of The Australian Paediatric Surveillance Unit, The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health and The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales.

## Corresponding author

Dr Suzy M Teutsch, Research Fellow, The Australian Paediatric Surveillance Unit, Kids Research Sydney Children’s Hospitals Network, Westmead Locked Bag 4001, Westmead NSW, Australia, 2145. Telephone: +61 2 9845 3025 Email: suzy.teutsch@health.nsw.gov.au

# References

1. Williams K, Elliott E. Role of the Australian Paediatric Surveillance Unit in monitoring communicable diseases of childhood. Commun Dis Intell. 1998;22(13):283–7.
2. Zurynski YA, Lester-Smith D, Festa MS, Kesson AM, Booy R, Elliott EJ. Enhanced surveillance for serious complications of influenza in children: role of the Australian Paediatric Surveillance Unit. Commun Dis Intell Q Rep. 2008;32(1):71–6.
3. Owen R, Barr IG, Pengilley A, Liu C, Paterson B, Kaczmarek M. Annual report of the National Influenza Surveillance Scheme, 2007. Commun Dis Intell Q Rep. 2008;32(2):208–26.
4. He S, Zurynski YA, Elliott EJ. Evaluation of a national resource to identify and study rare diseases: the Australian Paediatric Surveillance Unit. J Paediatr Child Health. 2009;45(9):498–504.
5. Nunez C, Morris A, Teutsch SM, McGregor S, Brotherton J, Novakovic D et al. Australian Paediatric Surveillance Unit annual report 2018. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.53 .
6. Australian Institute of Health and Welfare (AIHW). Australia’s children. (Cat. no. CWS 69.) [Internet.] Canberra: Australian Government, AIHW; 2020. [Accessed on 2 April 2020.] Available from: https://www.aihw.gov.au/reports/children-youth/australias-children.
7. Australian Bureau of Statistics (ABS). 3101.0 - Australian Demographic Statistics, Jun 2019. [Internet.] Canberra: Australian Government, ABS; 2019. Available from: https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun%202019?OpenDocument.
8. Desai S, Smith T, Thorley BR, Grenier D, Dickson N, Altpeter E et al. Performance of acute flaccid paralysis surveillance compared with World Health Organization standards. J Paediatr Child Health. 2015;51(2):209–14.
9. Roberts J, Hobday L, Ibrahim A, Aitken T, Thorley B. Annual report of the Australian National Enterovirus Reference Laboratory 2014. Commun Dis Intell Q Rep. 2017;41(2):E161–80.
10. Bao J, Thorley B, Elliott EJ, McIntyre P, Britton PN. Acute flaccid myelitis - has it gone unrecognised in Australian children? Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.22.
11. Australian Government Department of Health. Polio Surveillance. [Internet.] Canberra: Australian Government Department of Health; 2019. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-poliomyelitis.htm.
12. McRae JE, Quinn HE, Saravanos GL, McMinn A, Britton PN, Wood N, et al. Paediatric Active Enhanced Disease Surveillance (PAEDS) annual report 2016: Prospective hospital-based surveillance for serious paediatric conditions. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.5.
13. Munro SC, Trincado D, Hall B, Rawlinson WD. Symptomatic infant characteristics of congenital cytomegalovirus disease in Australia. J Paediatr Child Health. 2005;41(8):449–52.
14. McMullan BJ, Palasanthiran P, Jones CA, Hall BM, Robertson PW, Howard J et al. Congenital cytomegalovirus--time to diagnosis, management and clinical sequelae in Australia: opportunities for earlier identification. Med J Aust. 2011;194(12): 625–9.
15. Bartlett AW, Hall BM, Palasanthiran P, McMullan B, Shand AW, Rawlinson WD. Recognition, treatment and sequelae of congenital cytomegalovirus in Australia: an observational study. J Clin Virol. 2018;108;121–5.
16. Bartlett AW, McMullan B, Rawlinson WD, Palasanthiran P. Hearing and neurodevelopmental outcomes for children with asymptomatic congenital cytomegalovirus infection: a systematic review. Rev Med Virol. 2017. doi: http://doi.org/10.1002/rmv.1938.
17. Jones CA, Greenow-Raynes C, Isaacs D, on behalf of behalf of the Neonatal HSV Study Investigators and Contributors to the Australian Paediatric Surveillance Unit. Population-based surveillance of neonatal herpes simplex virus infection in Australia, 1997–2011. Clin Infect Dis. 2014;59(4):525–31.
18. James SH, Kimberlin DW. Neonatal herpes simplex virus infection epidemiology and treatment. Clin Perinatol. 2015;42(1):47–59.
19. Kimberlin DW, Lin C-Y, Jacobs RF, Powell DA, Frenkel LM, Gruber WC et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108(2):223–9.
20. Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med. 1991;324(7):444–9.
21. The Kirby Institute. Annual surveillance report on HIV, viral hepatitis and sexually transmissible infections in Australia 2017. Sydney; University of New South Wales, The Kirby Institute; 2017. Available from: https://kirby.unsw.edu.au/report/annual-surveillance-report-hiv-viral-hepatitis-and-stis-australia-2017.
22. Deverell M, Phu A, Zurynski YA, Elliott EJ and all chief investigators of APSU surveillance studies. Australian Paediatric Surveillance Unit Annual Report, 2014. Commun Dis Intell Q Rep. 2016;40(2):E216–20.
23. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2017. Sydney; University of New South Wales, The Kirby Institute; 2018. Available from: https://kirby.unsw.edu.au/report/hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-annual-surveillance.
24. Australian Government Department of Health. Eighth National HIV Strategy 2018–2022. Canberra: Australian Government Department of Health; 2018. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/$File/HIV-Eight-Nat-Strategy-2018-22.pdf.
25. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2019. Geneva: United Nations, UNAIDS; 2019. Available from: https://www.unaids.org/sites/default/files/media\_asset/2019-UNAIDS-data\_en.pdf.
26. Louie JK, Schechter R, Honarmand S, Guevara HF, Shoemaker TR, Madrigal NY et al. Severe pediatric influenza in California, 2003–2005: implications for immunization recommendations. Pediatrics. 2006;117(4):e610–8.
27. Australian Government Department of Health. Australian influenza surveillance report no. 12 – 23 September to 06 October 2019. Canberra: Australian Government Department of Health; 2019. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/ozflu-surveil-no12-19.htm#current.
28. Donne AJ, Clarke R. Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children. Int J STD AIDS. 2010;21(6):381–5.
29. Tjon Pian Gi REA, San Giorgi MRM, Slagter-Menkema L, van Hemel BM, van der Laan BFAM, van den Heuvel ER et al. Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11. Head Neck. 2015;37(11):1625–32.
30. Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowtz R et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018; 217(2):208–12.
31. Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M et al. Very low prevalence of vaccine human papillomavirus types among 18- to 35-Year old Australian women 9 years following implementation of vaccination. J Infect Dis. 2018;217(10):1590–600.
32. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi: https://doi.org/10.1136/bmj.f2032.
33. Khandaker G, Zurynski Y, Jones C. Surveillance for congenital rubella in Australia since 1993: cases reported between 2004 and 2013. Vaccine. 2014;32(50):6746–51.
34. Martin N, Durrheim D, Khandaker G, Butler M, Jones C. Using the two-source capture-recapture method to estimate the incidence and case ascertainment of congenital rubella syndrome in Australia, 1993–2013. Western Pac Surveill Response J. 2016;7(1):34–7.
35. Deverell M, Phu A, Zurynski YA, Elliott EJ and all chief investigators of Australian Paediatric Surveillance Unit surveillance studies. Australian Paediatric Surveillance Unit annual report, 2015. Commun Dis Intell Q Rep. 2017;41(2):E181–5.
36. Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F. Annual immunisation coverage report 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.47.
37. Forrest J, Mego S, Burgess M. Congenital and neonatal varicella in Australia. J Paediatr Child Health. 2000;36(2);108–13.
38. Khandaker G, Marshall H, Peadon E, Zurynski Y, Burgner D, Buttery J et al. Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia. Arch Dis Child. 2011;96(5),453–6.
39. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. [Internet.] Canberra: Australian Government Department of Health, ATAGI; 2018. Available from: <https://immunisationhandbook.health.gov.au/>.
40. Beard FH, Hendry AJ, Macartney K. Early success with room for improvement: influenza vaccination of young Australian children. *MJA* 2019;210(11),484-6.
41. National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in influenza vaccination practice in Australia. Sydney: Sydney Children’s Hospitals Network, NCIRS; 2018. Available from: http://www.ncirs.org.au/sites/default/files/2018-11/Influenza-history-July-2018.pdf.

# Appendix A. APSU conditions under surveillance

**Appendix A. APSU conditions under surveillance**

| Surveillance study – Case definition |
| --- |
| **Acute flaccid paralysis (AFP)**  Any child less than 15 years of age with acute flaccid paralysis in one or more limbs or acute onset of bulbar paralysis. All cases reported through APSU, NERL and PAEDS are reviewed by the PEP and classified as: confirmed poliomyelitis; non-polio AFP, polio-compatible or non-AFP. The NERL determines whether there is an infectious cause of AFP including enteroviruses. The PEP secretariat reports all Australian cases to the World Health Organization (WHO). |
| **Congenital cytomegalovirus (CMV) infection**  Congenital CMV: Any child from whom CMV is isolated in the first three (3) weeks of life, from urine, blood, saliva, or any tissue taken at biopsy.  Suspected congenital CMV: any child up to 12 months of age, in whom CMV is isolated from urine, blood, saliva or any tissue taken at biopsy and / or a positive serum immunoglobulin M (IgM) is found and in whom clinical features exist that may be due to intrauterine CMV infection.  Clinical features associated with congenital CMV infection include: prematurity, low birth weight, sensorineural deafness, other neurological abnormalities (encephalitis, microcephaly, developmental delay), seizures, microphthalmia, chorioretinitis, cataracts), hepatitis, hepatosplenomegaly, thrombocytopaenia, pneumonitis or myocarditis. |
| **Neonatal and young infant herpes simplex virus (HSV) infection**  Any neonate or infant aged less than 3 months of age (regardless of gestation) seen in the last month with laboratory confirmation of HSV infection and with either clinical evidence of HSV infection or laboratory confirmation of maternal perinatal HSV infection in an asymptomatic infant.  Laboratory confirmation is by detection of HSV by polymerase chain reaction (PCR) in a surface swab, respiratory specimen and/or sterile site (cerebrospinal fluid [CSF] or blood) (or by virus isolation), or by immunofluorescence.  Clinical evidence of neonatal HSV infection is one or more of: typical herpetic lesions of the skin, eye or mouth; evidence of disseminated infection (bleeding, bruising or coagulopathy, jaundice or elevated serum bilirubin, hepatosplenomegaly or elevated liver transaminases), pneumonitis (respiratory distress or chest radiograph) or encephalitis (lethargy, seizures, apnoea or abnormalities on neuroimaging or electroencephalogram [EEG]).  Laboratory evidence of maternal perinatal HSV infection is provided by detection of HSV in maternal genital swab and /or mother seroconverted to HSV or IgM positive in pregnancy or early postnatal period. |
| **Paediatric human immunodeficiency virus (HIV) infection and perinatal exposure to HIV in Australia**  Any child aged less than 16 years at diagnosis of HIV infection in Australia or any child born to a woman with diagnosed HIV infection. Children born to women with HIV infection and who are known to have been exposed to HIV perinatally, by in utero exposure or through breastfeeding, should be notified, even if they are subsequently confirmed as HIV antibody negative. |
| **Juvenile onset recurrent respiratory papillomatosis (JoRRP)**  Any infant or child under the age of 15 years diagnosed with juvenile onset recurrent respiratory papillomatosis (JoRRP) confirmed by endoscopy of the larynx and by histology. |
| **Severe complications of influenza in children < 15 years (June – September 2018)**  Any child aged less than 15 years with laboratory-confirmed influenza admitted to hospital with at least one of the following complications:   * Pneumonia (confirmed on X-ray or microbiology) * Oxygen requirement * Mechanical ventilation requirement * Laboratory proven secondary bacterial co-infection; bacteraemia; septicaemia; * Encephalitis / encephalopathy * Seizures (including simple febrile seizure, prolonged or focal seizure or status epilepticus) * Transverse myelitis * Polyneuritis / mononeuritis * Reye syndrome * Myocarditis; pericarditis; cardiomyopathy * Rhabdomyolysis * Purpura fulminans * Disseminated coagulopathy * Shock (requiring > 40 ml / kg fluid resuscitation) * Acute renal failure * Death, including death at presentation to hospital * Guillain-Barré syndrome |
| **Congenital rubella**  Any child or adolescent up to 16 years of age who, in the opinion of the notifying paediatrician, has definite or suspected congenital rubella, with or without defects, based on history, clinical and laboratory findings. |
| **Severe complications of varicella virus infection including neonatal and congenital varicella infection Neonatal varicella**  Any infant who has neonatal varicella based on history, clinical and/or laboratory findings in the first month of life without features of congenital varicella syndrome.  Features of neonatal varicella infection include pox-like rash which may be papulovesicular, vesiculopustular or haemorrhagic, and fever. Other systemic symptoms may be present. Complications of neonatal varicella include bacterial superinfection, neurological and haematological problems and general visceral involvement.  The diagnosis of neonatal varicella can be made when an infant in the first month of life presents with clinical features of varicella infection. There may be a history of maternal varicella infection in the last 1–4 weeks of pregnancy or contact with a varicella-infected person after birth.  The diagnosis can be confirmed by laboratory tests to detect:   * Viral antigen/viral isolate from scrapings of the skin lesions or viral DNA from lesion fluid. * Varicella-specific IgM in a serum sample from the infant (or from the contact).   **Congenital varicella**  Any stillbirth, newborn infant, or child up to the age of 2 years who, has definite or suspected congenital varicella infection, with or without defects and meets at least one of the following criteria:   * Cicatricial skin lesions in a dermatomal distribution and / or pox-like skin scars and / or limb hypoplasia. * Development of herpes zoster in the first year of life. * Spontaneous abortion, termination, stillbirth or early death following varicella infection during pregnancy.   Confirm varicella infection by one or more of the following:   * Detection of varicella-specific IgM antibodies in cord blood or in serum specimen taken in the first 3 months of life (only 25% of cases are positive). * Persistence of varicella-specific immunoglobulin G (IgG) antibody in a child aged beyond 6 months of age. * Identification of varicella virus in skin lesions or autopsy tissue. * History of maternal varicella during pregnancy or maternal contact with varicella in pregnancy in the mother of an infant with congenital abnormalities.   The following clinical signs may also be present in cases of congenital varicella syndrome:   * Microcephaly, hydrocephalus, cerebellar hypoplasia, motor or sensory deficits, sphincter dysfunction and peripheral nervous system defects. * Microphthalmia, cataracts, Horner’s syndrome, chorioretinitis, nystagmus, retinal scars, optic atrophy. * Gastrointestinal abnormalities including colonic atresia, hepatitis, liver failure. * Genito-urinary abnormalities. * Cardiovascular abnormalities. * Intrauterine growth retardation. |

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Tanja Farmer

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**Communicable Diseases Intelligence is produced by:   
Health Protection Policy Branch, Office of Health Protection, Australian Government Department of Health  
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2020 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>